We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+17.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.54B
AUM Growth
+$331M
Cap. Flow
-$396M
Cap. Flow %
-6.06%
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$49.7M
2
GEHC icon
GE HealthCare
GEHC
+$36.6M
3
MRNA icon
Moderna
MRNA
+$34.7M
4
BHVN icon
Biohaven
BHVN
+$33.4M
5
BSX icon
Boston Scientific
BSX
+$28M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.4M
2
UNH icon
UnitedHealth
UNH
+$64M
3
EVH icon
Evolent Health
EVH
+$36.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.5M
5
HUM icon
Humana
HUM
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Industrials 0.83%
3 Energy 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OLK
176
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
-217,256
Closed -$3.2M
GRCL
177
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
-38,000
Closed -$109K
PNT
178
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
-2,351,160
Closed -$15.7M
SGEN
179
DELISTED
Seagen Inc. Common Stock
SGEN
-22,000
Closed -$4.67M

Similar funds

Bellevue Group's Q4 2023 Portfolio in Review

As of Q4 2023, Bellevue Group held 179 positions worth $6.54B, up 5.3% from $6.21B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $396M in Q4 2023, closing 18 positions and reducing 89 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $34.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Biohaven worth $46M.

  • Bellevue Group's largest Q4 2023 buy was Biohaven: 1,075,000 shares worth $46M.
  • Bellevue Group added most to Immunocore in Q4 2023, an estimated $49.7M increase.
  • Bellevue Group's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $98.4M.
  • Bellevue Group fully exited Jazz Pharmaceuticals in Q4 2023, selling an estimated $34.5M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.54B portfolio in Q4 2023.
  • Bellevue Group opened 25 new positions and closed 18 in Q4 2023.
  • Bellevue Group's portfolio value rose 5.3% quarter-over-quarter to $6.54B.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.